The use of the antiparasitic drug ivermectin could lead to “large reductions” in COVID-19 deaths and may have a “significant impact” on the pandemic globally, according to a recent pre-print review based on peer-reviewed studies.
For the study (pdf), published June 17 in the American Journal of Therapeutics, a group of scientists reviewed the clinical trial use of ivermectin, which has antiviral and anti-inflammatory properties, in 24 randomized controlled trials involving just more than 3,400 participants. The researchers sought to assess the efficacy of ivermectin in reducing infection or mortality in people with COVID-19 or at high risk of getting it.
